<DOC>
	<DOCNO>NCT02601274</DOCNO>
	<brief_summary>A Phase I , open-label , multicenter dose-escalation study ass safety , tolerability , pharmacokinetics preliminary anti-tumor activity hmpl-309 patient advance solid tumor</brief_summary>
	<brief_title>Study Theliatinib ( HMPL-309 ) Patients With Advanced Solid Tumor</brief_title>
	<detailed_description>There two stage study : dose-escalation stage dose-expansion stage . Dose-escalation stage : hmpl-309 administer orally every day ( QD ) patient locally advance metastatic solid tumor standard therapy either exist proven ineffective intolerable . Dose-expansion stage : hmpl-309 administer orally 300mg every day ( QD ) patient patient EGFR positive oesophageal carcinoma .</detailed_description>
	<criteria>Histopathology confirm solid tumor Failed standard treatment standard treatment uncontrolled , recurrent and/or metastatic advance tumor ( whatever previous surgery condition ) Doseescalation stage : &lt; 300mg/day cohort requiremnet pathological pattern &gt; 300mg/day cohort require NCSLC , head net squamous carcinoma , oesophageal carcinoma Doseexpansion stage require oesophageal carcinoma Age 1875 performance status 0 , 1 , bad within 7days Life expect &gt; 3 month write informed consent form voluntarily Lab test within 1 week enrol , hemoglobin ＜9 g/dL , platelet count &lt; 750,000/mm3 &lt; 150000/mm3 , Total bilirubin≥1.5× upper limit normal , Serum creatinine high normal range Diastolic pressure≥150mmHg systolic pressure≥100mmHg whatever antihypertension drug use , Serum potassium ( whenever potassium implement ) , serum calcium ( ionic albumintype calcium ) serum magnesium outside normal range ( whenever implement ) Within previous 4 week treat systemic antitumor therapy , radiotherapy , immune therapy , biological hormonal therapy , clinical trial . But exclude therapy , Prostate cancer treat hormonal therapy GnRH ( gonadotropinreleasing hormone ) analogue antagonist Hormone replacement therapy oral contraceptive Palliative radiotherapy bone metastasis within 2 week Prior documental evidence resistance EGFRTKI ( epidermal growth factor receptortyrosine kinase inhibitor ) Unrecovered previous therapy relate toxicity to≤ CTCAE ( Common Toxicity Criteria Adverse Effects ) 0 1or unrecovered previous surgery Any CNS ( central nervous system ) metastasis uncontrolled symptom Known dysphagia drug malabsorption Active infection acute pneumonia , hepatitis B active period APTT ( activate partial thromboplastin time ) and/or INR ( international normalize ratio ) , PT≥2 upper limit normal ( include patient treated anticoagulation treatment ) ocular surface diseases dry eye syndrome skin disease obvious symptom sign significant cardiovascular disease , include IIIV atrioventricular block , acute myocardial infarction within 6 month , significant angina Coronary artery bypass graft Known exist interstitial lung disease Female patient pregnant feeding , childbearing potential patient pregnant test positive Any abnormal clinical laboratory patient unsuitable attend trial sine opinion investigator Patients unable comply protocol since significant psychological psychogenic abnormal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>